Dreyfus Ashby & Co. Welcomes Jules Taylor Wines to Portfolio
NEW YORK--(BUSINESS WIRE)--#dreyfusashby--Dreyfus Ashby & Co., a leading wine and spirits importer with a distinguished…
4 years ago
ACT Games Reveals Promotion Video for ZOIDS WILD NFT ARENA: the First NFT Game Using ZOIDS WILD Franchise
- An NFT game that utilizes ZOIDS WILD and ZOIDS WILD ZERO, popular iterations of…
4 years ago
ACT Games Reveals Promotion Video for ZOIDS WILD NFT ARENA: the First NFT Game Using ZOIDS WILD Franchise
- An NFT game that utilizes ZOIDS WILD and ZOIDS WILD ZERO, popular iterations of…
4 years ago
Vietnam Rice Industry Report 2022-2031: Development Environment, Supply and Demand, Import and Export, Market Competition, Major Companies, Outlook – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Research Report on Vietnam's Rice Industry 2022-2031" report has been added to ResearchAndMarkets.com's…
4 years ago
upGrad Closes Investment Round of USD 210 Million
MUMBAI, India--(BUSINESS WIRE)--#ACC--upGrad, Asia's higher edtech major, has announced a fresh round of fundraise from…
4 years ago
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total…
4 years ago
Cyclo Therapeutics to Present at the China NPC Association Meeting
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage…
4 years ago
Plastec Technologies Reports Fiscal 2022 First Half Results; Announces Extension of Securities Repurchase Plan
HONG KONG--(BUSINESS WIRE)--Plastec Technologies, Ltd. (OTCBB: PLTYF) (the “Company”) today reported unaudited financial results for…
4 years ago
HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) announced today that the first patient…
4 years ago
Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) Published in Future Oncology
Pivotal study will offer insights on the effectiveness of a unique monopegylated interferon as an…
4 years ago